BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 32893093)

  • 1. The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer.
    Goff SL; Danforth DN
    Clin Breast Cancer; 2021 Feb; 21(1):e63-e73. PubMed ID: 32893093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune cell quantitation in normal breast tissue lobules with and without lobulitis.
    Degnim AC; Brahmbhatt RD; Radisky DC; Hoskin TL; Stallings-Mann M; Laudenschlager M; Mansfield A; Frost MH; Murphy L; Knutson K; Visscher DW
    Breast Cancer Res Treat; 2014 Apr; 144(3):539-49. PubMed ID: 24596048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.
    Burugu S; Asleh-Aburaya K; Nielsen TO
    Breast Cancer; 2017 Jan; 24(1):3-15. PubMed ID: 27138387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer.
    García-Martínez E; Gil GL; Benito AC; González-Billalabeitia E; Conesa MA; García García T; García-Garre E; Vicente V; Ayala de la Peña F
    Breast Cancer Res; 2014 Nov; 16(6):488. PubMed ID: 25432519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
    Agahozo MC; van Bockstal MR; Groenendijk FH; van den Bosch TPP; Westenend PJ; van Deurzen CHM
    Mod Pathol; 2020 Feb; 33(2):196-205. PubMed ID: 31375764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients.
    Zhu S; Lin J; Qiao G; Xu Y; Zou H
    Tumour Biol; 2015 Sep; 36(10):7907-13. PubMed ID: 25953262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
    Chen XY; Yeong J; Thike AA; Bay BH; Tan PH
    Breast Cancer Res Treat; 2019 Aug; 177(1):17-27. PubMed ID: 31134489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent.
    Agahozo MC; Westenend PJ; van Bockstal MR; Hansum T; Giang J; Matlung SE; van Deurzen CHM
    Mod Pathol; 2020 Sep; 33(9):1773-1782. PubMed ID: 32341499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome.
    Huang Y; Ma C; Zhang Q; Ye J; Wang F; Zhang Y; Hunborg P; Varvares MA; Hoft DF; Hsueh EC; Peng G
    Oncotarget; 2015 Jul; 6(19):17462-78. PubMed ID: 25968569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development.
    Degnim AC; Hoskin TL; Arshad M; Frost MH; Winham SJ; Brahmbhatt RA; Pena A; Carter JM; Stallings-Mann ML; Murphy LM; Miller EE; Denison LA; Vachon CM; Knutson KL; Radisky DC; Visscher DW
    Clin Cancer Res; 2017 Jul; 23(14):3945-3952. PubMed ID: 28126725
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma.
    Igari F; Sato E; Horimoto Y; Takahashi Y; Isomura T; Arakawa A; Kitano S; Saito M
    Hum Pathol; 2017 Dec; 70():129-138. PubMed ID: 29122657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of PD-1 on CD4
    Zhao YJ; Zhang J; Shi F; Hu ZP; Wu JP; Wu GJ; Wang RB; Zhou Q; Chang H; Li YN; Song QK
    J Immunol Res; 2018; 2018():5690258. PubMed ID: 30069490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.
    Nelson MA; Ngamcherdtrakul W; Luoh SW; Yantasee W
    Cancer Metastasis Rev; 2021 Jun; 40(2):519-536. PubMed ID: 33963482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.
    Thompson ED; Taube JM; Asch-Kendrick RJ; Ogurtsova A; Xu H; Sharma R; Meeker A; Argani P; Emens LA; Cimino-Mathews A
    Mod Pathol; 2017 Nov; 30(11):1551-1560. PubMed ID: 28731046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast.
    Kim M; Choi HY; Woo JW; Chung YR; Park SY
    Sci Rep; 2021 Sep; 11(1):18007. PubMed ID: 34504204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations.
    Hussein MR; Hassan HI
    J Clin Pathol; 2006 Sep; 59(9):972-7. PubMed ID: 16935972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immune microenvironment of breast ductal carcinoma in situ.
    Thompson E; Taube JM; Elwood H; Sharma R; Meeker A; Warzecha HN; Argani P; Cimino-Mathews A; Emens LA
    Mod Pathol; 2016 Mar; 29(3):249-58. PubMed ID: 26769139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.
    Zhong L; Xie L; Yang Z; Li L; Song S; Cao D; Liu Y
    BMC Cancer; 2020 Aug; 20(1):766. PubMed ID: 32799825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.